Pharma / Biotech

FDA Approves Kanjinti Biosimilar to Herceptin

The FDA granted approval to trastuzumab-anns (Kanjinti, Amgen/Allergan) biosimilar for all approved indications of the reference product, Herceptin (Genentech): the treatment (as adjuvant) of HER2-overexpressing metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Source link

Related posts

Quantitative determination and pharmacokinetic study of fusaricidin A in mice plasma and tissues using ultra-high performance liquid chromatography-tandem mass spectrometry.


FLUOXETINE (Fluoxetine Hydrochloride) Capsule [Lake Erie Medical DBA Quality Care Products LLC]


Tailoring Nutrition to Special Patient Populations


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy